0PQ Stock Overview
A biotechnology company, focuses on the discovery and development of novel therapeutic medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
ProQR Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.47 |
| 52 Week High | US$4.00 |
| 52 Week Low | US$1.45 |
| Beta | 0.22 |
| 1 Month Change | -26.61% |
| 3 Month Change | 67.64% |
| 1 Year Change | 37.92% |
| 3 Year Change | -65.75% |
| 5 Year Change | n/a |
| Change since IPO | -43.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0PQ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.3% | -3.5% | -2.0% |
| 1Y | 37.9% | -14.7% | 6.9% |
Return vs Industry: 0PQ exceeded the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 0PQ exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| 0PQ volatility | |
|---|---|
| 0PQ Average Weekly Movement | 37.6% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0PQ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0PQ's weekly volatility has increased from 21% to 38% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 157 | Daniel de Boer | www.proqr.com |
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets.
ProQR Therapeutics N.V. Fundamentals Summary
| 0PQ fundamental statistics | |
|---|---|
| Market cap | €260.81m |
| Earnings (TTM) | -€23.94m |
| Revenue (TTM) | €18.39m |
14.4x
P/S Ratio-11.1x
P/E RatioIs 0PQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0PQ income statement (TTM) | |
|---|---|
| Revenue | €18.39m |
| Cost of Revenue | €0 |
| Gross Profit | €18.39m |
| Other Expenses | €42.33m |
| Earnings | -€23.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 100.00% |
| Net Profit Margin | -130.21% |
| Debt/Equity Ratio | 18.1% |
How did 0PQ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 02:50 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ProQR Therapeutics N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathan Aschoff | B. Riley Wealth |
| Eliana Merle | Cantor Fitzgerald & Co. |
| Steven Seedhouse | CGS International |